Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Jul 26, 2024 9:01am

95 Views

Post# 36149476

RE:RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

Absolutely, Venture! Promotion is key from reliable and respected sources. Not hype from retail investors, day traders etc..... just good old positive vibes from industry experts,
Now, if Noteable were one of those individuals.....his contributions would have put us on the radar and given us some positive momentum

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals